Claris Lifesciences, one of the largest sterile injectables pharmaceutical companies in India, witnessed a rise in share price on Monday after it has reached a settlement and license agreement, ending all pending litigation with Fresenius Kabi USA, Inc. With reference to the alleged infringement of a patent relating to Propofol for injection, 10mg/ml, which is a generic version of DIPRIVAN.

Shares of the company are trading at Rs 328.70, up Rs 19.7, or 6.38% at the Bombay Stock Exchange (BSE) on Monday at 10:34 a.m.

The scrip has touched an intra-day high of Rs 334 and low of Rs 314.80. The total volume of shares traded at the BSE is 357,000.